Cejas et al., 2012 - Google Patents
Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapyCejas et al., 2012
- Document ID
- 11269280997601721935
- Author
- Cejas P
- Lopez-Gomez M
- Aguayo C
- Madero R
- Moreno-Rubio J
- de Castro Carpeno J
- Belda-Iniesta C
- Barriuso J
- Moreno Garcia V
- Diaz E
- Burgos E
- Gonzalez-Baron M
- Feliu J
- Publication year
- Publication venue
- Current cancer drug targets
External Links
Snippet
Patients with metastatic Colorectal Cancer (mCRC), in which primary tumors are KRAS mutated, have no response to anti-EGFR therapy. However, less than half of mCRC patients with KRAS wild-type primary tumors respond to anti-EGFR therapy. Other downstream …
- 206010028980 Neoplasm 0 title abstract description 86
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cejas et al. | Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy | |
Bardelli et al. | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | |
Watson et al. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance | |
US20220213219A1 (en) | Bruton's Tyrosine Kinase as Anti-Cancer Drug Target | |
Park et al. | Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer | |
Tamborini et al. | Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas | |
JP2018508183A (en) | Compositions and methods for treating and diagnosing chemotherapy-resistant cancer | |
Projetti et al. | Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas | |
US10442862B2 (en) | Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents | |
WO2014028222A1 (en) | Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug | |
JP2018516870A (en) | Method for treating a patient having a mutation in the extracellular domain of epidermal growth factor receptor (EGFR) using a combination of three fully human monoclonal anti-EGFR antibodies | |
JP2017526916A (en) | Diagnosis of cancer | |
CN110225984A (en) | Identify the method and therapeutic choice of risk of cancer | |
EP4291902A2 (en) | Biomarkers for cancer treatment | |
EP3722417A1 (en) | Cancer spheroid production method and method for selecting colon cancer patients | |
WO2014145254A2 (en) | Falz for use as a target for therapies to treat cancer | |
Isobe et al. | PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma | |
US20160206646A1 (en) | Bruton's Tyrosine Kinase as Anti-Cancer Drug Target | |
WO2023137447A1 (en) | Alk gene fusions and uses thereof | |
CN105188742A (en) | Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents | |
Wang et al. | GEFT protein expression in digestive tract malignant tumors and its clinical significance | |
Felsberg et al. | Prognostic role of epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas | |
Emmerich | VCAN Accumulation and Proteolysis Play Critical Roles in Directing CD8+ TILs and Response to ICIs in Solid Tumors | |
US20150218647A1 (en) | Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug | |
Zhang et al. | MiR-323a-3p Inhibits Tumor Growth and Gefitinib Resistance Acquisition by Targeting EGFR/ErbB3 in Colorectal Cancer |